Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04726488
Other study ID # Periareolar Minimally Invasive
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date February 2021
Est. completion date February 2023

Study information

Verified date January 2021
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Overall Goal: To study the feasibility and safety of "periareolar minimally invasive surgery" protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach). - Objective1: Test the hypothesis that, the periareolar approach is more feasible and safer than the inframammary approach. - Objective2: Identify risk factors that are predictive of the need for periareolar approach. - Objective3: Assess outcomes and postoperative results of both periareolar and inframammary approach.


Description:

The first successful cardiac operation was performed in 1896, in Germany by Rehn (1), followed by the first successful cardiac valve operation in 1912 by Tuffier (2) and the first successful mitral valve operation in 1923 (3). In 1956, Lillehei repaired multiple valvular lesions through a right thoracotomy using cardiopulmonary bypass (4). In the 1990s, the success of laparoscopic operations in general surgery renewed an interest in minimally invasive approaches for cardiac surgery. Navia and Cosgrove (5) and Cohn et al. (6) performed the first minimally invasive valve operations via the right parasternal and transsternal approaches. Remarkably, excellent exposure was achieved through smaller incisions, thereby making complex valve repair possible and safe. In 1996, Carpentier et al. (7) performed the first video-assisted mitral valve repair through a minithoracotomy using ventricular fibrillation. With more experience, video-assisted, 2-dimensional endoscopes and robotics were introduced by Carpentier (7) and Chitwood (8,9). In 2009 Poffo et al (10,11) describe a new technique of minimally invasive cardiac surgery. He and his colleagues adopting periareolar access for mitral valve surgery since 2006 and published this technique in 2009. However, due to its feasibility and safety, was soon incorporated as an ideal access for other cardiac pathologies such as tricuspid valve disease, atrial septal defect, atrial fibrillation, and pacemaker leads endocarditis. This led Poffo and his colleagues to publish a long-term result on his technique in 2018 supporting the use of periareolar access as a routine surgical technique for correction of several cardiac pathologies, especially in women. (12)


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 102
Est. completion date February 2023
Est. primary completion date September 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients undergoes mitral or tricuspid valve surgery. - lesion of right side of the heart. Exclusion Criteria: - patients undergoing aortic valve or CABG surgery. - surgery of left side of the heart.

Study Design


Related Conditions & MeSH terms

  • Periareolar Minimally Invasive Cardiac Surgery

Intervention

Procedure:
Periareolar Approach in Minimally Invasive Cardiac Surgery (PAMI Technique)
To study the feasibility and safety of "periareolar minimally invasive surgery" protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach).
inframammary approach
To study the feasibility and safety of "periareolar minimally invasive surgery" protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach).

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Outcome

Type Measure Description Time frame Safety issue
Primary Duration of surgery start from skin incision to cardiopulmonary bypass initiation 2 hours
Secondary rate of surgical site complications wound infection, dehiscence, seroma three month